Write in a clean editor, then format for Clinical Proteomics in one click — DocuGuru applies the official BMC (BioMed Central) template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Clinical Proteomics is a peer-reviewed journal published by BMC (BioMed Central), covering Advanced Proteomics Techniques and Applications, Glycosylation and Glycoproteins Research, Mass Spectrometry Techniques and Applications. Over its lifetime it has published 774 papers, which have received 17,035 citations.
| Publisher | BMC (BioMed Central) |
|---|---|
| Reference style | Numbered (Vancouver) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. Clinical Proteomics. 2023;12(3):45–58.
Formats any DOI in Clinical Proteomics style. No sign-up. |
| Publishes research in | Advanced Proteomics Techniques and Applications Glycosylation and Glycoproteins Research Mass Spectrometry Techniques and Applications Advanced Biosensing Techniques and Applications Metabolomics and Mass Spectrometry Studies |
| ISSN | 1542-6416 |
| Citation impact (2-yr) | 4.02 |
| h-index | 57 |
| i10-index | 410 |
| Article processing charge | $1,950 |
| Open access | Yes — indexed in DOAJ |
| Top institutions publishing here | Johns Hopkins University |
| Journal website | www.springer.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Tremendous efforts have been made over the past few decades to discover novel cancer biomarkers for use in clinical practice. However, a striking discrepancy exists between the effort directed toward biomarker discovery and the number of markers that make it into clinical practice. One of the confounding issues in translating a novel discovery into clinical…
The greatest unmet needs in biomarker discovery are those discoveries that lead to the development of clinical diagnostic tests. These clinical diagnostic tests can provide early intervention when a patient would present otherwise healthy (e.g., cancer or cardiovascular disease) and aid clinical decision making with improved clinical outcomes. The past two decades have seen significant…
Cancer biomarkers have transformed current practices in the oncology clinic. Continued discovery and validation are crucial for improving early diagnosis, risk stratification, and monitoring patient response to treatment. Profiling of the tumour genome and transcriptome are now established tools for the discovery of novel biomarkers, but alterations in proteome expression are more likely to reflect…
O-linked β-D-N-acetylglucosamine (O-GlcNAc) modification (O-GlcNAcylation) onto serine and threonine residues of proteins is an important post-translational modification (PTM), which is involved in many crucial biological processes including transcription, translation, proteasomal degradation, and signal transduction. Aberrant protein O-GlcNAcylation is directly linked to the pathological progression of chronic diseases including diabetes, cancer, and neurodegenerative disorders. Identification, site…
BACKGROUND: One of the new roles for enzymes in personalized medicine builds on a rational approach to cancer biomarker discovery using enzyme-associated aberrant glycosylation. A hallmark of cancer, aberrant glycosylation is associated with differential expressions of enzymes such as glycosyltransferase and glycosidases. The aberrant expressions of the enzymes in turn cause cancer cells to produce…
